4 - CODEXIS, INC. (0001200375) (Issuer)

3 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

3 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 11:00 am ET. A live webcast of the event will be available in the Investor Relations section of the Company's website, https://ir.codexis.com. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading provider of enzymatic solutions for efficient and

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligon

REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company's Board of Directors. "We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "Raymond brings a deep understanding of the commercial and regulatory landscape as well as direct experience in oligonucleotide manufacturing." "Codexis and its ECO Synthesis platform represent the next generation of innovat

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasdaq on the gran

REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences. The Stifel 2024 Healthcare Conference (New York, NY) Monday, November 18, 2024, at 2:25 pm ET, management will participate in a fireside chat The Jefferies London Healthcare Conference (London, UK) Tuesday, November 19, 2024, at 9:30 am GMT, management will participate in a fireside chat The 15th Annual Craig-Hallum Alpha Select Conference (New York, NY) Tuesday, November 19, 2024, management will host 1x1 investor me

Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Codexis had a strong third quarter, in which we surpassed product revenue goals, welcomed two new, high

REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will have three data presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany. The Company's presentations will showcase real-world application of the ECO Synthesis™ manufacturing platform to enable the manufacture of siRNA through both ligation and sequential enzymatic synthesis. Attendees of the conference may visit with the Codexis team at Booth #709 in the exhibition hall. Appointments may be made in advance by clicking he

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 350,175 shares of Codexis common stock and (ii) 80,138 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. Included in this total are equity awards for Codexis' newly appointed Chief Financial Officer, Georgia Erbez. As part of h

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

4 - CODEXIS, INC. (0001200375) (Issuer)

REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company's Board of Directors. "We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "Raymond brings a deep understanding of the commercial and regulatory landscape as well as direct experience in oligonucleotide manufacturing." "Codexis and its ECO Synthesis platform represent the next generation of innovat

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company's existing at-the-market facility during the quarter ended September 30, 2024. These funds are in addition to the $73.2 million in cash, cash equivalents and investments on hand as of June 30, 2024. In

REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management. "We are honored to have Carole join Codexis as the newest member of our Strategic Advisory Board," sa

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company's Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals. This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company's strategic direction, providing critical insights to inform the continued development of Codexis' ECO Synthesis™ manufacturing platform. "We are thrilled to have Masad and Jim lend their decades of experience

REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company's financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. "I am excited to announce the addition of Sri to Codexis as we continue to build a top executive leadership team with the strategic acumen, operational experience and commercial mindset to deliver on our pr

REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. "Stewart's deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background, and viewpoints," said Byron Dorgan, Chair of the Board of Codexis. "In particular, her experience advising publicly traded pharmaceutical and genomic therapy companies will be valuable as we continu

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Margaret ("Meg") Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. In this role, Ms. Fitzgerald will lead the Company's legal and compliance functions and provide strategic guidance to the Board of Directors and executive management team. She will report directly to Dr. Stephen Dilly, President and CEO of Codexis. "Meg is a seasoned legal executive and leader with extensive experience on both routine and complex legal matters," said Dr. Dilly. "Meg brings invaluabl

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital s

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligon

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.

Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Codexis had a strong third quarter, in which we surpassed product revenue goals, welcomed two new, high

REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (int

Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform by End of Year REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "We're pleased that our second quarter revenues are exactly in-line with our expectations. As a result, we are reiterating our 2024 financial guidance and look forward to a strong second half

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for at least 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be

Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. "We are off to a strong start this year with our first quarter financial results, and we are

REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available f

Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of Double-stranded RNA Ligase and Return to Growth for Pharmaceutical Manufacturing REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update. "W

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the ca

Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. 

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Codexis (NASDAQ:CDXS) with a Overweight rating and announces Price Target of $11.

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:CDXS) with a Buy and maintains $9 price target.

Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 52.94 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $17.073 million which beat the analyst consensus estimate of $13.660 million by 24.98 percent. This is a 31.51 percent increase over sales of $12.982 million the same period last year.

Gainers Cardiff Oncology (NASDAQ:CRDF) shares moved upwards by 28.6% to $2.27 during Thursday's after-market session. The company's market cap stands at $101.4 million. As per the press release, Q4 earnings came out today. Kineta (NASDAQ:KA) shares increased by 20.6% to $0.99. The market value of their outstanding shares is at $10.2 million. Burning Rock Biotech (NASDAQ:BNR) stock rose 10.84% to $0.88. The market value of their outstanding shares is at $90.3 million. Y-mAbs Therapeutics (NASDAQ:YMAB) shares moved upwards by 8.68% to $18.15. The market value of their outstanding shares is at $791.7 million. The company's, Q4 earnings came out today. Lucy Scientific Discovery (NASDAQ:LSDI

Benchmark analyst Robert Wasserman upgrades Codexis (NASDAQ:CDXS) from Hold to Buy and announces $9 price target.

The Benchmark Company downgraded Codexis from Buy to Hold

Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

The Benchmark Company upgraded Codexis from Hold to Buy

The Benchmark Company downgraded Codexis from Buy to Hold

TD Cowen downgraded Codexis from Outperform to Market Perform and set a new price target of $4.00 from $21.00 previously

H.C. Wainwright downgraded Codexis from Buy to Neutral

Piper Sandler resumed coverage of Codexis with a rating of Overweight and set a new price target of $35.00

Cowen resumed coverage of Codexis with a rating of Outperform

HC Wainwright & Co. reiterated coverage of Codexis with a rating of Buy and set a new price target of $38.00 from $33.00 previously

8-K - CODEXIS, INC. (0001200375) (Filer)

10-Q - CODEXIS, INC. (0001200375) (Filer)

8-K - CODEXIS, INC. (0001200375) (Filer)

8-K - CODEXIS, INC. (0001200375) (Filer)

8-K - CODEXIS, INC. (0001200375) (Filer)

S-8 - CODEXIS, INC. (0001200375) (Filer)

10-Q - CODEXIS, INC. (0001200375) (Filer)

8-K - CODEXIS, INC. (0001200375) (Filer)

8-K - CODEXIS, INC. (0001200375) (Filer)

EFFECT - CODEXIS, INC. (0001200375) (Filer)